Elotuzumab for the treatment of multiple myeloma

Yucai Wang; Larysa Sanchez; David S. Siegel; Michael L. Wang

doi:10.1186/s13045-016-0284-z

Elotuzumab for the treatment of multiple myeloma

Yucai Wang
, Larysa Sanchez
, David S. Siegel
, Michael L. Wang

School of Medicine

Rutgers - The State University of New Jersey, New Brunswick
University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Review article › peer-review

55 Scopus citations

Abstract

Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.

Original language	English
Article number	55
Journal	Journal of Hematology and Oncology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1186/s13045-016-0284-z
State	Published - 15 Jul 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1186/s13045-016-0284-z

Cite this

@article{bebaa01f7ef74c03810f4a8d49a0f03e,

title = "Elotuzumab for the treatment of multiple myeloma",

abstract = "Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.",

author = "Yucai Wang and Larysa Sanchez and Siegel, \{David S.\} and Wang, \{Michael L.\}",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = jul,

day = "15",

doi = "10.1186/s13045-016-0284-z",

language = "English",

volume = "9",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central Ltd",

number = "1",

}

TY - JOUR

T1 - Elotuzumab for the treatment of multiple myeloma

AU - Wang, Yucai

AU - Sanchez, Larysa

AU - Siegel, David S.

AU - Wang, Michael L.

PY - 2016/7/15

Y1 - 2016/7/15

N2 - Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.

AB - Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.

UR - https://www.scopus.com/pages/publications/84978654911

U2 - 10.1186/s13045-016-0284-z

DO - 10.1186/s13045-016-0284-z

M3 - Review article

C2 - 27417553

AN - SCOPUS:84978654911

SN - 1756-8722

VL - 9

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 55

ER -

Elotuzumab for the treatment of multiple myeloma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this